NASDAQ:TORCresTORbio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.27 -0.03 (-1.30 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$2.19Now: $2.27▼$2.3550-Day Range$2.02MA: $2.21▼$2.4952-Week Range$0.86Now: $2.27▼$11.96Volume558,300 shsAverage Volume1.31 million shsMarket Capitalization$82.73 millionP/E RatioN/ADividend YieldN/ABeta2.59 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingresTORbio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, resTORbio has a potential upside of 54.2% from its current price of $2.27.Amount of Analyst CoverageresTORbio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesresTORbio has received 141 “outperform” votes. (Add your “outperform” vote.)Underperform VotesresTORbio has received 139 “underperform” votes. (Add your “underperform” vote.)Community SentimentresTORbio has received 50.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote “Outperform” if you believe TORC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldresTORbio does not currently pay a dividend.Dividend GrowthresTORbio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, resTORbio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.80% of the stock of resTORbio is held by insiders.Percentage Held by Institutions36.27% of the stock of resTORbio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for resTORbio are expected to grow in the coming year, from ($1.24) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of resTORbio is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of resTORbio is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioresTORbio has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TORC Previous Symbol CUSIPN/A CIK1720580 Webwww.restorbio.com Phone857-315-5528Debt Debt-to-Equity RatioN/A Current Ratio30.25 Quick Ratio30.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book1.01Profitability EPS (Most Recent Fiscal Year)($2.41) Net Income$-82,740,000.00 Net MarginsN/A Return on Equity-79.90% Return on Assets-73.09%Miscellaneous EmployeesN/A Outstanding Shares36,446,000Market Cap$82.73 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:TORC Rates by TradingView Receive TORC News and Ratings via Email Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. resTORbio (NASDAQ:TORC) Frequently Asked Questions How has resTORbio's stock been impacted by COVID-19 (Coronavirus)? resTORbio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TORC stock has increased by 94.0% and is now trading at $2.27. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of resTORbio? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for resTORbio. When is resTORbio's next earnings date? resTORbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for resTORbio. How were resTORbio's earnings last quarter? resTORbio, Inc. (NASDAQ:TORC) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.15. View resTORbio's earnings history. What price target have analysts set for TORC? 6 analysts have issued 12-month target prices for resTORbio's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate resTORbio's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 54.2% from the stock's current price. View analysts' price targets for resTORbio. Has resTORbio been receiving favorable news coverage? Media coverage about TORC stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. resTORbio earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about resTORbio. Are investors shorting resTORbio? resTORbio saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 744,700 shares, an increase of 7.5% from the June 15th total of 693,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 3.5% of the shares of the company are sold short. View resTORbio's Current Options Chain. Who are some of resTORbio's key competitors? Some companies that are related to resTORbio include Tocagen (TOCA), Progenics Pharmaceuticals (PGNX), Calithera Biosciences (CALA), Wave Life Sciences (WVE), MannKind (MNKD), MEI Pharma (MEIP), ANI Pharmaceuticals (ANIP), Magenta Therapeutics (MGTA), Neptune Wellness Solutions (NEPT), Affimed (AFMD), Bicycle Therapeutics (BCYC), Rigel Pharmaceuticals (RIGL), Pivot Pharmaceuticals (PVOTF), Seres Therapeutics (MCRB) and Avadel Pharmaceuticals (AVDL). View all competitors. What other stocks do shareholders of resTORbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include SCYNEXIS (SCYX), Abeona Therapeutics (ABEO), Novavax (NVAX), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Denali Therapeutics (DNLI), Opko Health (OPK), VBI Vaccines (VBIV) and Agile Therapeutics (AGRX). Who are resTORbio's key executives? resTORbio's management team includes the following people: Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. CommunicationDr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69) When did resTORbio IPO? (TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is resTORbio's stock symbol? resTORbio trades on the NASDAQ under the ticker symbol "TORC." Who are resTORbio's major shareholders? resTORbio's stock is owned by many different retail and institutional investors. Top institutional investors include Strategic Wealth Designers (0.07%). View institutional ownership trends for resTORbio. Which institutional investors are buying resTORbio stock? TORC stock was purchased by a variety of institutional investors in the last quarter, including Strategic Wealth Designers. View insider buying and selling activity for resTORbio. How do I buy shares of resTORbio? Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is resTORbio's stock price today? One share of TORC stock can currently be purchased for approximately $2.27. How big of a company is resTORbio? resTORbio has a market capitalization of $82.73 million. The company earns $-82,740,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. What is resTORbio's official website? The official website for resTORbio is www.restorbio.com. How can I contact resTORbio? resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
